Kathy Hochul taps new board of directors Nassau County hospital after state's hostile takeover
Rabinowitz is one of four appointees joining the newly revamped NUMC board, Hochul's office announced.
Konstantinos 'Dean' Mihaltses, a longtime hospital executive who worked at NYC Health + Hospitals in Queens; Lisa Warren, president of Placid LLC real estate development; and Amy Flores, a JP Morgan Chase vice president, were also tapped for the posts.
'NUMC is a vital lifeline for so many on Long Island, and today we are taking long-overdue steps to ensure it has the leadership and oversight it needs to thrive,' Hochul said in a statement.
'These new appointments, and the new authority granted to the state and NIFA, will help ensure accountability, responsible fiscal management and high-quality care for the communities NUMC serves. Stuart Rabinowitz is a respected and visionary leader, and I can't think of a better person to help lead this next chapter for NUMC.'
Hochul plans to replace the entire 11-member board of the Nassau Health Care Corp., or NuHealth, which oversees the teaching hospital.
The other seven will be chosen by the governor, who will first meet with Democratic state and lawmakers to consider candidates.
The appointments take effect Sunday, and coincide with a new state law that overhauls NuHealth's leadership, bolsters state oversight and 'sets a path forward' for getting NUMC's finances back on track.
The news comes a day after NUMC's CEO and nine other hospital leaders resigned.
'NUMC is a critical safety-net institution that has suffered from years of dysfunction and mismanagement,' Rabinowitz said. 'I'm grateful to Governor Hochul for the trust she's placed in me, and I'm eager to get to work with my fellow board members to restore public confidence, implement long-overdue reforms and put this hospital back on a path to stability and excellence.'
Rabinowitz, a Columbia Law grad, was Hofstra's president for more than 20 years.
During his tenure at the Long Island university, the former constitutional law professor oversaw the creation of a medical school and raised Hofstra's national profile, securing it as the host site for three US presidential debates.
The new board is expected to meet on Monday.
Between now and Dec. 1, 2026, the board will need to submit a study 'exploring options to strengthen NUMC,' according to Hochul's statement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Goldman: Q2 Earnings Snapshot
NEW YORK (AP) — NEW YORK (AP) — Goldman Sachs Group Inc. (GS) on Wednesday reported second-quarter earnings of $3.72 billion. The New York-based company said it had earnings of $10.91 per share. The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $9.43 per share. The investment bank posted revenue of $31.27 billion in the period. Its revenue net of interest expense was $14.58 billion, also exceeding Street forecasts. Six analysts surveyed by Zacks expected $13.5 billion. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on GS at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
an hour ago
- Business Upturn
LIS Technologies Inc. Appoints Distinguished Nuclear Expert Lloyd Jollay as its UF6 Systems Manager
Lloyd Jollay's addition continues LIS Technologies' initiative to build a management team consisting of veteran nuclear industry specialists and leaders. Oak Ridge, Tennessee, July 16, 2025 (GLOBE NEWSWIRE) — LIS Technologies Inc. ('LIST' or 'the Company'), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, today announced that Lloyd Jollay, a seasoned nuclear engineering professional with over 30 years of experience in nuclear safety, materials management, and advanced fuel cycle operations, has been appointed as it UF 6 Systems Manager. 'LIST's patented CRISLA technology has the potential to support the revitalization and growth of the nation's nuclear-fuel supply chain,' said Lloyd Jollay, UF 6 Systems Manager of LIS Technologies Inc. 'The Company has taken a leading role in this industry's innovation and decisive steps to rebirth, demonstrate and subsequently commercialize its technology. I look forward to putting my industry experience to work in support of this mission.' Former Vice President of Isotopes and Nuclear Fuel Cycle at Boston Government Services, Lloyd Jollay led the development of nuclear safety programs and provided licensing support for emerging advanced reactor and isotope production initiatives. His extensive background includes managing criticality safety programs, supporting the peaceful use and transport of uranium materials, and advising on nuclear nonproliferation strategies within the DOE and NNSA complex. Figure 1 – LIS Technologies Inc. Appoints Seasoned Nuclear Engineering Professional Lloyd Jollay as its UF 6 Systems Manager. In his prior roles, Mr. Jollay held multiple leadership positions at the Y-12 National Security Complex in Oak Ridge, Tennessee. His work included directing nuclear material applications, overseeing high-enriched uranium (HEU) supply and return efforts, and managing multimillion-dollar budgets supporting domestic and international nuclear nonproliferation. He also led criticality safety teams, supporting safe nuclear operations through rigorous documentation, evaluations, and compliance with regulatory bodies including NPO, NNSA, and the DNFSB. Mr. Jollay holds an MBA and a B.S. in Engineering Physics from the University of Tennessee, Knoxville, where he also completed coursework toward an M.S. in Nuclear Engineering. He is a certified Six Sigma Black Belt, has completed advanced training in SCALE and MCNP, and maintains active membership in the American Nuclear Society and the Institute of Nuclear Materials Management. 'I'm pleased to welcome Lloyd to LIS Technologies,' said Jay Yu, Executive Chairman and President of LIS Technologies Inc. 'Bringing in seasoned leaders is essential as we scale, and Lloyd's depth of experience in the nuclear sector will strengthen our management team at a critical juncture. His track record and commitment to the industry will be instrumental as we work to position LIST at the forefront of America's nuclear fuel supply chain revitalization.' 'Lloyd's addition comes at a pivotal moment as we move toward the next phase of our technology's development,' said Christo Liebenberg, CEO and Co-Founder of LIS Technologies Inc. 'With decades of experience in nuclear operations and non-proliferation, and his many connections with nuclear entities in the Oak Ridge area and nationwide, he brings along fresh perspective to help guide our work responsibly. Lloyd has consistently championed innovative solutions throughout his career, and I am pleased to have him on the team.' About LIS Technologies Inc. LIS Technologies Inc. (LIST) is a USA based, proprietary developer of a patented advanced laser technology, making use of infrared lasers to selectively excite the molecules of desired isotopes to separate them from other isotopes. The Laser Isotope Separation Technology (L.I.S.T) has a huge range of applications, including being the only USA-origin (and patented) laser uranium enrichment company, and several major advantages over traditional methods such as gas diffusion, centrifuges, and prior art laser enrichment. The LIST proprietary laser-based process is more energy-efficient and has the potential to be deployed with highly competitive capital and operational costs. L.I.S.T is optimized for LEU (Low Enriched Uranium) for existing civilian nuclear power plants, High-Assay LEU (HALEU) for the next generation of Small Modular Reactors (SMR) and Microreactors, the production of stable isotopes for medical and scientific research, and applications in quantum computing manufacturing for semiconductor technologies. The Company employs a world class nuclear technical team working alongside leading nuclear entrepreneurs and industry professionals, possessing strong relationships with government and private nuclear industries. In Dec 2024, LIS Technologies Inc. was selected as one of six domestic companies to participate in the Low-Enriched Uranium (LEU) Enrichment Acquisition Program. This initiative allocates up to $3.4 billion overall, with contracts lasting for up to 10 years. Each awardee is slated to receive a minimum contract of $2 million. For more information please visit: For further information, please contact: Email: [email protected]Telephone: 800-388-5492Follow us on X Platform Follow us on LinkedIn
Yahoo
2 hours ago
- Yahoo
Henry Schein's Quarterly Earnings Preview: What You Need to Know
Melville, New York-based Henry Schein, Inc. (HSIC) provides healthcare products and services to office-based dental and medical practitioners, as well as alternative sites of care worldwide. With a market capitalization of $8.6 billion, the company operates through four segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. HSIC is all geared up to report its Q2 2025 results on Tuesday, August 5. Before this event, analysts project that the company will report an adjusted EPS of $1.19, down 3.3% from $1.23 in the year-ago quarter. The company has surpassed or matched Wall Street's bottom-line estimates in each of the last four quarters, which is impressive. Dear Nvidia Stock Fans, Mark Your Calendars for July 16 Seeking Passive Income? This 'Strong Buy' Dividend Stock Yields 8.6%. How to Buy Tesla for a 13% Discount, or Achieve a 26% Annual Return Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For fiscal 2025, analysts expect HSIC to report an adjusted EPS of $4.86, representing a 2.5% year-over-year increase from $4.74 in fiscal 2024. Moreover, in fiscal 2026, the company's adjusted EPS is expected to increase 8.6% year-over-year to $5.28. HSIC stock has grown 7.3% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 10.9% gain but outperforming the Health Care Select Sector SPDR Fund's (XLV) 10.3% decline over the same time frame. HSIC stock rose 2% following the release of its Q1 2025 results on May 5. The company's net sales declined marginally year-over-year to $3.2 billion, missing the consensus estimate. Meanwhile, its adjusted EPS grew 4.5% from the prior-year quarter to $1.15, surpassing analysts' estimate by 3.6%. Analysts are moderately optimistic about HISC's stock, with an overall "Moderate Buy" rating. Among 14 analysts covering the stock, five recommend "Strong Buy," eight advise 'Hold,' and one suggests 'Strong Sell.' The mean price target of $77 indicates a 9% potential upside from HSIC's current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
